VANCOUVER, BC, March 10, 2021 /CNW/ – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company“), a biotechnology company that is a global leader in the emerging field of serotonergic psychedelic medicine, is pleased to announce that it has been approved for trading on the OTCQB Venture Market effective today, March 10, 2021. “The up-listing of our shares to…


Previous articleGroup Ketamine-Assisted Psychotherapy: Practice and Promise of a New Frontier
Next articleOctarine Bio announces closing of extended seed round financing of $1.2 million USD with an uptick in valuation due to significant investor demand.